MISTER SPEX

FY 2024 Results Presentation

27 March 2025





### Agenda

### SpexFocus update

**Financial update for 2024** 

Strategic agenda for 2025

Guidance

Q&A




### **FY 2024 Highlights and Insights**

**Germany Revenue: 0% FY'24** € 217m Net revenue (LfL +2%) -€ 5.8m Adj. EBITDA Financial Representing -3% in 2024 International Revenue: -13% Performance **Transformation: Building the Future Restructuring: Laying the Foundation** Strengthening optical expertise **Cost reduction and efficiency improvements SpexFocus Update** Portfolio rationalization and market exits Improving store operations and service quality **Elevating customer experience Rightsizing operations for a leaner organization Tobias Krauss** Nicola Brandolese **Management Update** will assume the role of CEO on April 1, 2025 will take over as Chairman of the Supervisory Board




### **Recap: 2024 was the year of Transition**

Q3 2024 Financial Results






### **SpexFocus: Rightsizing and Portfolio Rationalization**



1. Includes HQ, Operations (Logistics) and Customer Service 2. Nürnberg, Saarbrücken (Europa-Galerie), Hamburg




### **SpexFocus: Roll out of SpexPro drives AOV**






### **SpexFocus: Lower discounts supports Gross Margin**






### **SpexFocus: Optimizing Commercial Strategies**





# **SpexFocus: We see first signs of success in Store business: 2M 2025**

German Store operations, Like-for-like Panel



\*Excludes - Hamburg (closed Nov'23) and Saarbrücken (closed Jan'24)



## **Financial update**




## Germany: store growth of 5% overall and 2% LFL


### Germany

Net revenue (€m)

Segment reporting



**Category development** 



Prescription glasses (PG)
Contact lenses (CL)
Sunglasses (SG)
Miscellaneous services

#### Focus on 2024 dynamics

- Total store sales: +5% growth
- LfL<sup>1</sup> Growth: 2% for the year
- **Prescription glasses:** Store-based sales grew by 7% in 2024. Online sales were positive for the first nine months but came under pressure in Q4 due to a lens campaign in Q4 2023.
- **Sunglasses** store-based sales grew by 5% in 2024. Online sales were roughly flat for the first nine months, but came under pressure in Q4, following discount detox
- Store in Nürnberg closed end of February


1. LFL: Store cohort '16 - '22




## International impacted by stores closures in H2

### International

Net revenue (€m)



**Category development** 



#### Focus on 2024 dynamics

- Double-digit declines month-overmonth following store closure announcements in August
- Store closures: All stores closed by year end leading to ~ € 5 million in one off store closure costs




### 2024 is impacted by restructuring measures

		Reported			Adjusted	
	2023	2024	Change	2023	2024	Change
Gross Profit Margin	50.6%	49.8%	(0.8)pp	50.6%	49.8%	(0.8)pp
Personnel expense	(27.7)%	(28.7)%	(1.0)pp	(25.7)%	(26.3)%	(0.6)pp
Marketing expense	(11.1)%	(10.8)%	0.3pp	(11.1)%	(10.8)%	0.3pp
Other operating expense	(16.7)%	(23.8)%	(7.1)pp	(16.2)%	(17.5)%	(1.3)pp
EBITDA	(2.1)%	(11.4)%	(9.3)pp			
Adjusted EBITDA	0.4%	(2.7)%	<b>(3.1)pp</b>	0.4%	(2.7)%	(3.1)pp

#### Focus on 2024 dynamics


- Gross profit margin: ~60bps gain in 9M was largely reversed due to lower volumes from discount detox and a smaller year-end supplier bonus. Meanwhile, margin-accretive prescription glasses grew to 41% of FY 2024 revenue
- **Personnel expense:** Improved by ~€ 1 million after adjustments
- Marketing expense: Improved by ~€ 1.4 million after adjustments
- **Other operating expenses**: impacted by rental increases for the store and the HQ
- Adjusted EBITDA: Impacted by lower sales, resulting in a reduced year-end supplier contribution

### **Cash flow development in 2024**






## **Optimizing Inventory for Efficiency & Growth**



Reduction from ~150 to ~100 brands And from 20k SKUs to 12k SKUs Outlet Section online





### **Recap: 2024 was the year of Transition**

#### Spex Focus: Business model transformation

- In 2024, we launched the SpexFocus program to drive profitability by targeting overhead and store-related costs. This included ~€ 13M in one-off (€ 9M SpexFocus and € 3.4M inventory) transformation costs, primarily from store closures and overhead reductions.
- We expect an underlying improvement of over €20 million in profitability, with the majority of the impact in 2025 and some continued benefits in 2026

#### FY2024 – A Transition Year

- Revenue & Profitability: Overall revenue declined by 3%, with International offline business down 13%. AEBITDA weakened as gross profit came down due to decreased discounting.
- Cash & Liquidity: Cash balance remains solid at € 72M, while FCF declined by € 38M, including ~€ 13M in SpexFocus one-off expenses.

#### 3 New Steering for EBIT

- Focus on EBIT Over EBITDA: Mister Spex is shifting to EBIT as the key performance indicator to provide a clearer view of business performance.
- Enhancing Transparency & Long-Term Value: Prioritizing EBIT drives transparency on sustainable profitability and creates a foundation for long-term value creation.



### In 2025 we will continue to focus on SpexFocus pillars...

### In 2025 we will continue to focus on SpexFocus pillars

Improving cost and operating efficiency

**Building a profitable store network** 

Focusing on optical expertise

Therefore, building a foundation where our growth is powered by our own cash flows



# In 2025 we will continue to focus on SpexFocus pillars

### Building a profitable store network by working on conversion, upselling and product mix



#### Increasing efficiency and reduction of complexity

**Cashless stores** 21 additional stores to become fully cashless from February Goal is to reduce cost and complexity

**Streamlined governance** (sales director & district managers)

ц Ц

#### "Empowered to sell"

Anamnesis - systematically capture customer needs Goal is to increase conversion and 2nd pair share

#### **2nd Pair Push for Prescription Glasses**

Goal is to increase AOV by increasing average items per prescription order by >5%

 $\bigotimes$ 

**First Metrics and Insights** (Jan and Feb)


#### +2% like-for-like growth

**Only 3 campaigns** in Q1'25 vs ~5 campaigns in Q1'24

>500 bps decrease in discounts

### ... and we will sharpen our vision and to lay the foundation for the future

### We started as an "online story"...





# ... in 2024 we started repositioning towards becoming an optician...




### ... and focusing on profitability and cash flow in 2025

Source: Company information, Statistisches Bundesamt (2020), ZVA Eyewear Study (2019)




### ... to start a dynamic growth from 2026 onwards by becoming The Optician for Your Life

The core of our business will remain prescription glasses, sunglasses and contact lenses but we will expand optical expertise and services




\*Der Optiker deines Lebens

# In 2025 we will build the basis for next years to come : Eye health check



### **Guidance 2025**



Price repositioning and continuous reduction of discounts will lead to a negative impact on the Online revenues The company will continue **to reduce its cost base** and aims **to improve profitability** in 2025. The greatest progress is expected to come from an **increase in the average order value** (AOV) and an **optimization of the gross margin**, driven by price adjustments, a refined product mix strategy, and an **expansion of the high-margin lens portfolio**.



### To conclude

#### **2024 was a Transition Year**

In 2024, we launched the SpexFocus program to drive profitability by targeting overhead and store-related costs. This included ~€ 13M in one-off transformation costs, primarily from store closures and overhead reductions



In 2025, we will continue to implement SpexFocus which will especially impact H1 2025, as we actively reposition away from discounting Q1: Continuation of Q4 trends, while is slightly supported by improving gross margin



# Looking ahead

### **Reporting and Conferences**


8 May	Q1 2025 financial results
28 August	H1 2025 financial results
13 November	Q3 2025 financial results
Conference:	
12 - 14 May	EF Equity Forum (Frankfurt)






## **Revenue supported by resilient unit economics**

Reduction is primarily due to the new strategic direction under the SpexFocus program, including adjustments to marketing channels



Reduction is due to lower sales and the negative impact of store closures on the international segment



AOV rising to € 101.7, with improvements seen across all product categories, this increase offsets the reduced number of orders

<sup>1</sup> Customers who ordered in the last 12 months excluding cancellations <sup>2</sup> Orders after cancellations and after returns <sup>3</sup> Calculated as revenues divided by number of orders over the last 12 months



## Q4 2024

		Reported			Adjusted	
	Q4 2023	Q4 2024	Change	Q4 2023	Q4 2024	Change
Gross Profit Margin	56.4%	50.8%	(5.9)pp	50.6%	49.8%	(0.8)pp
Personnel expense	(31.2)%	(36.1)%	(4.9)pp	(29.2)%	(33.5)%	(4.3)pp
Marketing expense	(9.7)%	(9.6)%	0.1pp	(9.7)%	(9.6)%	0.1pp
Other operating expense	(20.4)%	(45.9)%	(25.5)pp	(19.8)%	(21.1)%	(1.3)pp
EBITDA	(2.7)%	(38.6)%	(35.9)pp			
Adjusted EBITDA	0.0%	(8.9)%	(8.9)pp	0.0%	(8.9)%	(8.9)pp

#### Focus on Q4 2024 dynamics

- Gross profit margin: lower volumes from discount detox and a smaller year-end supplier bonus
- **Personnel expense:** small decrease year-onyear, after adjustments
- Marketing expense: ~600k improvement
- Other operating expenses: ~ 600k improvement after adjustments
- Adjusted EBITDA: Impacted by lower sales, resulting in a reduced year-end supplier contribution





### **Consolidated statement of profit or loss**

#### Consolidated statement of profit or loss

in€k	Note	2024	2023	Change
Revenue	1.	216,752	223,530	-3%
Other own work capitalized		3,203	4,826	-34%
Other operating income	3.	1,357	1,507	-10%
Operating income		221,313	229,863	-4%
Cost of materials	10.	-108,736	-110,373	-1%
Personnel expenses	2., 14.	-62,310	-61,970	1%
Other operating expenses	3.	-74,991	-62,213	21%
Earnings before interest, taxes, depreciation and amortization (EBITDA)		-24,724	-4,693	>100%
Depreciation, amortization and impairment and reversals of impairment	6., 7., 8., 16.	-60,440	-43,026	40%
Earnings before interest and taxes (EBIT)		-85,164	-47,720	78%
Finance income	4.	3,843	3,898	-1%
Finance costs	4.	-4,468	-4,318	3%
Financial result		-625	-421	49%
Earnings before taxes (EBT)		-85,790	-48,141	78%
Income tax income	5.	931	256	>100%
Loss for the period		-84,859	-47,884	77%
Thereof loss attributable to the shareholders of Mister Spex SE		-84,859	-47,884	77%
Basic and diluted earnings per share (in EUR)	26.	-2,56	-1,45	77%
Consolidated statement of comprehensive income				
in€k		2024	2023	
Loss for the period		-84,859	-47,884	77%
Other comprehensive income/loss possibly to be reclassified to profit and loss in subsequeriods	uent			
Exchange differences on translation of foreign financial statements		235	-160	>-100%
Other comprehensive income/loss		235	-160	>-100%

-84,624

-84,624

-48,044

-48,044

76%

76%



Total comprehensive loss

Thereof loss attributable to the shareholders of Mister Spex SE

### **Consolidated statement of cash flows**

2023

-47,884

-3,898 4,313

-256

7,468

8,402

18,996

8,160

2,215

-2.457

4,362

7,168

-908

-3,263

3,344

6,037

-16,299

275

#### Consolidated statement of cash flows Note 2024 in€k Operating activities -84,859 Loss for the period Adjustments for: Finance income 4 -3,843Finance costs 4 4.468 5. Income tax income -931 Amortization and impairment of intangible assets 6. 18,952 Depreciation and impairment of property, plant and equipment 7. 9,618 Depreciation and impairment of 16. right-of-use assets 27,517 Impairment of goodwill 6. 4,353 Non-cash expenses for share-based payments and remeasurement of financial 15. 1,192 liabilities Increase (+)/decrease (-) in provisions 18. 107 Increase (-)/decrease (+) in inventories 10. 4,249 Increase (-)/decrease (+) in other assets 11. 6,713 Increase (+)/decrease (-) in trade payables and other liabilities 15.,17. -2,779Income tax paid 5. -664 Interest paid -3,400Interest received 3.008

#### Consolidated statement of cash flows

in € k	Note	2024	2023
Investing activities			
Investments in property, plant and equipment	7.	-1,589	-7,464
nvestments in intangible assets	6.	-4,788	-7,142
Cash flow from investing activities		-6,377	-14,606
Financing activities			
Payments issue of shares or other equity instruments		-183	0
Cash received from capital increases, net of transaction costs	14.	0	277
Cash received from borrowings		0	1,941
Cash outflows from repayment of borrowings	16.	-1,253	-928
Payment of principal portion of lease liabilities	16.	-14,411	-9,860
Cash flow from financing activities		-15,846	-8,569

Net change in cash	-38,522	-17,138
Cash and cash equivalents at the beginning of the period	110,654	127,792
Cash and cash equivalents at the end of the period	72,133	110,654



Cash flow from operating activities

### **Consolidated statement of financial position**

Consolidated statement of financial position

#### Consolidated statement of financial position Assets in€k Note 31 Dec 2024 31 Dec 2023 60.479 122.673 Non-current assets 6. 316 4,669 Goodwill Intangible assets 6. 6,405 21,412 7. 12,927 22,845 Property, plant and equipment 16. 36,254 69,126 Right-of-use assets Other financial assets 9. 4.577 4,620 110,791 157,751 Current assets Inventories 28,249 32,498 Right of return assets 1. 807 783 9. 1,188 2,213 Trade receivables 9. 975 Other financial assets 1,317 11. 9,790 Other non-financial assets 5.639 Tax refund claims 838 1,458 Cash and cash equivalents 12. 72,133 110,654


171,270

280,424


in€k	Note	31 Dec 2024	31 Dec 2023
Equity	13.	71,837	155,453
Issued capital		34,176	34,075
Capital reserves		330,858	329,951
Other reserves		-1,019	-1,254
Accumulated loss		-292,178	-207,319
Non-current liabilities		57,532	77,168
Provisions	18.	1,886	1,839
Lease liabilities	16.	52,908	70,161
Liabilities to banks	15.	640	1,120
Other financial liabilities	15.	2,026	3,059
Other non-financial liabilities	17.	72	21
Deferred tax liabilities	5.	0	969
Current liabilities		41,901	47,803
Provisions	18.	802	1,006
Trade payables	15.	9,957	17,935
Refund liabilities	15.	2,187	1,974
Lease liabilities	16.	12,563	15,328
Liabilities to banks	15.	240	0
Other financial liabilities	15.	3,144	2,157
Contract liabilities	1.	2,456	1,821
Other non-financial liabilities	17.	10,551	7,582
Total equity and liabilities		171,270	280,424

Total assets


### Market data



370 businesses have had to close in the last three years. During this time, chain stores have continued to make significant market share compared to the independent single independent retailers.



<sup>1</sup> Source: ZVA Branchereport Augernoptik: Märkte, Consumer und Trends 2023|2024 and Consumer und Trends 2022|2023



### Myopia management is increasingly important

2010: 28% of the population has myopia By 2050 it is expected to be ~50%

#### Share of eyewear wearers

